Completed PHASE2 INTERVENTIONAL 1-arm NCT01882504

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum

Sponsor: XOMA (US) LLC

Conditions Pyoderma Gangrenosum

Interventions gevokizumab

Updated 6 times since 2017 Last updated: Feb 2, 2016 Started: May 31, 2013 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Pyoderma Gangrenosum, this trial is completed. The trial is conducted by XOMA (US) LLC and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XOMA (US) LLC

Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Arlington, United States , Baltimore, United States , Birmingham, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Houston, United States , Knoxville, United States and 9 more locations